Americans' becoming more aware of GLP-1 drugs like Ozempic, Wegovy: Survey
The YouGov poll, released Friday, shows that at least 80 percent of respondents have heard at least 'a little bit' about semaglutide, a medication used to treat Type 2 diabetes that also helps a user to shed weight.
In March 2023, only 60 percent of Americans were aware of the drug. A year later, in March 2024, that number had jumped to 70 percent, the pollster noted. The latest survey also shows that the share of those who have heard 'a lot' about the medication has nearly doubled since 2023, increasing to 41 percent from 23 percent.
Just 36 percent of respondents say they know someone who has taken semaglutide. Around 14 percent listed a family member took the medicine, 16 percent named a friend, 11 percent identified an acquaintance and 7 percent said they had taken it themselves, according to the poll. Several also noted they knew a user in more than one category.
Women are more likely than men, 43 percent to 29 percent, to know someone — including themselves — who has taken a GLP-1 agonist drug, per the survey.
The weight loss medications — including Wegovy, Ozempic, Zepbound and others — have been available since 2005 but have only in the past few years been used to treat obesity. The drugs work by mimicking a hormone in the body — glucagon-like peptide-1 — that stimulates insulin secretion and reduces appetite.
Possible side effects of taking the medication include nausea, diarrhea, vomiting, and constipation.
While semaglutide is currently only prescribed for weight loss or treating diabetes, early research is pointing to possible benefits for a host of other issues, including treatment for addiction, neurodegenerative diseases and conditions that affect the heart, kidney or liver.
The latest survey found that roughly a quarter of respondents said they would be 'very' or 'somewhat' interested in taking the medication as a weight loss treatment.
About a third of Americans have either taken the drug or said they would be interested in trying it. On the other side, about 17 percent said they were 'not very' interested in the medication and 45 percent signaled they were not at all interested.
A separate poll from last September found that around a quarter of adults in the U.S. would consider using weight loss medications without consulting their doctor.
The YouGov analysis is based on an online survey conducted from May 22-25 among 1,109 adults in the U.S. The margin of error for the full sample is 4 percentage points.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
12 minutes ago
- Newsweek
Weight Loss Drugs Like Ozempic Could Have Additional Health Benefit
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Could diabetes and weight loss drugs like Ozempic (semaglutide) also protect the brain from stroke damage—or even help prevent strokes entirely? Three new studies suggest they might, with the potential of GLP-1 receptor agonists—such as Ozempic—extending beyond just blood sugar regulation and weight loss. According to a May 2024 KFF Health Tracking Poll, approximately one in eight U.S. adults (12 percent) report having used a GLP-1 agonist. Usage rates are notably higher among individuals with chronic health conditions: 43 percent of adults with diabetes, 25 percent with heart disease, and 22 percent of those who have been diagnosed as overweight or obese in the past five years have taken one of these medication. Now, emerging research suggests they may also offer significant neurological benefits. A stock image of woman injecting a Semaglutide Pen in her stomach. A stock image of woman injecting a Semaglutide Pen in her stomach. JNemchinova/iStock / Getty Images Plus Lower Stroke Mortality in Ozempic Users The first study, led by researchers at the University of Wisconsin-Madison, analyzed stroke outcomes among patients taking Ozempic. The team compared data from two large sources: the University of Wisconsin's health system and a global health collaborative. Among more than two million stroke patients from the global dataset, those on Ozempic were found to have a dramatically lower initial death rate—just 5.26 percent compared to 21.61 percent for non-users. Long-term survival rates also favored Ozempic users, with a 77.5 percent survival rate versus 30.95 percent for those not on the drug. The university's own data mirrored this trend: stroke mortality among Ozempic users was less than 5 percent, compared to more than 26 percent in non-users. Could Ozempic Reduce the Risk of Stroke? A second study, also from the University of Wisconsin-Madison, looked at whether Ozempic could lower the chance of experiencing a stroke in the first place. Researchers analyzed emergency department records nationwide, identifying individuals likely using Ozempic and comparing their stroke incidence rates. The study found that potential Ozempic users had significantly lower odds of suffering a stroke. The research team now hopes to confirm these findings using pharmacy records, which would more precisely track who is prescribed the drug. Brain Bleed Protection and Cognitive Benefits The final study, conducted by the University of Texas Medical Branch in Galveston, extended the investigation to brain hemorrhages—both spontaneous bleeds and those caused by aneurysms. The researchers examined the health record of patients who had experienced a stroke or hemorrhage for up to two years after the event in question. Their analysis indicated that GLP-1 agonists were associated with reduced risks of cognitive decline, seizures, repeat hemorrhages and death. "This research could introduce a new perspective to the discussion of preventing and mitigating the devastating effects of stroke and related brain injuries," paper author and neurosurgeon Dr. Matias Costa said in a statement. A Promising Frontier for GLP-1 Drugs Dr. Ahmed Elbayomy, a research fellow in neurological surgery at the University of Wisconsin-Madison and lead author on two of the studies said in a statement: "More research is certainly needed, but seeing the potential protection offered by these medications is a fascinating finding." As use of semaglutide-based drugs like Ozempic and Wegovy continues to expand, the possibility that they might also protect the brain could usher in a new era of neurological prevention—offering more than just metabolic benefits. Do you have a tip on a health story that Newsweek should be covering? Do you have a question about GLP-1 agonists? Let us know via health@
Newsweek
12 minutes ago
- Newsweek
Donald Trump Doubles Down on Mathematically Impossible Drug Price Cuts
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. President Donald Trump has doubled down on his claim of reducing drug prices by amounts that are mathematically impossible. Trump told reporters on Sunday that his administration had cut the price of some prescription drugs by as much as 1,500 percent. "Well, one of the things they're going to be talking about pretty soon are the tremendous drop in drug prices. You know, we've cut drug prices by 1,200, 1,300, 1,400, 1,500 percent. I don't mean 50 percent. I mean 14-, 1,500 percent," the president said. When asked to clarify the president's remarks, White House spokesperson Kush Desai told Newsweek, "It's an objective fact that Americans are paying exponentially more for the same exact drugs as people in other developed countries pay, and it's an objective fact that no other Administration has done more to rectify this unfair burden for the American people." Why It Matters Trump's remarks signal a misunderstanding of how pricing and percentages work, which could undermine public confidence in his ability to tackle problems such as drug pricing. President Donald Trump speaks with reporters near Air Force One at the Lehigh Valley International Airport in Allentown, Pennsylvania, on August 3. President Donald Trump speaks with reporters near Air Force One at the Lehigh Valley International Airport in Allentown, Pennsylvania, on August To Know Reducing the price of a drug by 100 percent would make it free, and a reduction greater than 100 percent suggests pharmaceutical companies would pay their customers to take their prescription drugs. Commenting on Trump's claims, Jeffrey Frankel, a professor of capital formation and growth at Harvard University, told Newsweek that the numbers were "indeed mathematically impossible." On Friday, the president made similar claims of bringing drug prices down by "1,000 percent, 1,200 percent" in an interview with Newsmax's Rob Finnerty. That came a day after the White House said Trump had written to the heads of 17 pharmaceutical companies outlining steps they needed to take to bring down the prices of drugs sold in the U.S. to match the lowest price paid by a group of other economically advanced countries. According to a fact sheet the White House released on Thursday, Trump's letters said the pharmaceutical manufacturers' proposals for implementing his May executive order—which seeks to achieve "most favored nation" pricing in the United States—had "fallen short." However, it did not mention the percentage reductions the president has discussed in recent days. What People Are Saying Jeffrey Frankel, a professor of capital formation and growth at Harvard University, told Newsweek: "They are indeed mathematically impossible. If he cut prices 90 percent, the drugs would cost 1/10 as much as before. If 100 percent, then they would cost zero. If cutting 1,000 percent means a thing, then it means that the drug company pays you (a lot) to take the drug." He added: "It's almost as if Trump is making fun of his supporters, seeing what increasingly absurd statements he can get away with." Justin Wolfers, a professor of economics and public policy at the University of Michigan, told Newsweek: "This is not a question for an economist, but rather a sixth grader. After all, the Common Core curriculum standard states that students should know how to 'find a percent of a quantity as a rate per 100 (e.g., 30 percent of a quantity means 30/100 times the quantity).'" Wolfers added: "I just checked with my sixth grader (Oliver Wolfers), and he confirmed that he has studied percentages and that the president's math does not make sense 'because then the prices would be negative.' He added, 'Is he an idiot?' before returning to watching YouTube. Oliver's father agrees with Oliver's mathematical analysis and encourages him to use more positive language when engaging with fellow kids." Pau Pujolas, a professor of economics at McMaster University, told Newsweek: "If your grocery bill is $100 and you get a 50 percent reduction in price, you pay $50. If you get a 75 percent reduction, you pay $25. If you get a 99 percent reduction, you pay $1. If you get a 100 percent reduction, you pay $0. You can't get a reduction larger than that ... so 1,200 percent doesn't make sense. "Talking about bad math: Firing Erika McEntarfer, the director of the Bureau of Labor Statistics (BLS), is way worse than a POTUS not knowing how to operate with basic percentages. Let's not miss the forest for the trees." President Donald Trump said at a Republican dinner in July: "This is something that nobody else can do. We're gonna get the drug prices down—not 30 or 40 percent, which would be great, not 50 or 60 percent. No, we're gonna get them down 1,000 percent, 600 percent, 500 percent, 1,500 percent. Numbers that are not even thought to be achievable." The White House fact sheet said: "From this point forward, President Trump will only accept from drug manufacturers a commitment that provides American families immediate relief from vastly inflated drug prices and an end to the freeriding by European and other developed nations on American innovations." Journalist James Surowiecki wrote on X in response to Trump's comments on Sunday: "It's not just that the math here is nonsensical. It's that Trump hasn't actually cut drug prices yet at all. He's literally just sent letters to drugmakers telling them to cut prices. Does he know that and is lying? Or is he deluded? We have no idea." What Happens Next Trump and the White House have not clarified what he means when he says drug prices will come down by as much as 1,500 percent. The president's letters to pharmaceutical companies give them a 60-day window to present a viable plan to reduce U.S. drug prices.
Business Wire
41 minutes ago
- Business Wire
HealthTap Launches Virtual Direct Primary Care for Organizations, Creating Most Accessible and Affordable Comprehensive PCP Program
SUNNYVALE, Calif.--(BUSINESS WIRE)-- HealthTap, a leading virtual healthcare provider delivering accessible, high-quality primary care, today announced the launch of its Direct Virtual Primary Care for Organizations program, enabling employers, cost-sharing entities or any other member-based organizations to offer high-quality, AI-enabled virtual primary care without complex integrations or infrastructure overhauls. HealthTap Launches Virtual Direct Primary Care for Organizations, Creating Most Accessible and Affordable Comprehensive PCP Program. The formal launch follows the recent enactment of U.S. H.R. 1 (The Big Beautiful Bill Act) that enables organizations like employers to cover direct primary care (DPC) memberships while still preserving employees' HSA eligibility, potentially saving significantly on downstream healthcare costs. Primary care is widely recognized as one of the most powerful tools to improve long-term health outcomes and control healthcare costs. Yet nearly a third of Americans lack access, contributing to fragmented care, delayed diagnoses and preventable health crises. HealthTap's model addresses this challenge by making relationship-based primary care easier to access, more affordable to offer and more scalable across populations. With a pricing guarantee that matches or beats existing solutions, HealthTap virtual DPC offers one of the most accessible and cost-effective ways to embed comprehensive, longitudinal primary care into any benefit design. The program includes a national medical group consisting of board-certified doctors, mental and behavioral health care, 365-day urgent care, chronic condition management and built-in AI tools to improve decision support and patient outcomes. Initial partners have already seen meaningful results from the program, with thousands of patients initiating care and returning to the same provider. Notably, 96% of Christian Healthcare Ministries (CHM) members who started with a primary care doctor returned to the same provider—far exceeding national continuity benchmarks. 'Working with HealthTap has been an incredibly positive experience, helping solidify value for our members,' said Charity C. Beall, Vice President and Chief Financial Officer of Christian Healthcare Ministries, the largest and longest-serving health cost sharing ministry in the nation. 'The HealthTap team is responsive, steady and kind, and truly invested in our mission, offering practical support including nutrition and lifestyle changes that empower our members to thrive. We're looking forward to growing our partnership to drive members toward building long-term relationships with a primary care doctor.' CrowdHealth, a disruptive health cost-funding platform, also is a virtual DPC partner, giving its members a virtual-first, relationship-based model for primary care across state lines. 'Our members can now build lasting, trusted relationships with the doctor of their choice—no matter where they are,' said Andy Schoonover, CEO of CrowdHealth. 'That kind of ongoing connection has been missing from most virtual care. HealthTap makes it seamless.' The HealthTap Direct Primary Care for Organizations program is designed for rapid deployment and delivers: Nationwide access to virtual PCPs and urgent care; Member choice and continuity, with the ability to select and stay with the same doctor; Annual wellness visits and evidence-based prevention protocols; Mental and behavioral health care integrated under PCP supervision; Medical record aggregation, referral workflows and specialist navigation; Comprehensive member engagement support; AI-powered patient intake and visit preparation through HealthTap's Dr. AI; Flexible pricing models, including membership or usage-based; Customizable copays; Guaranteed affordability, with pricing that meets or beats existing PCP rates; and Out-of-the-box or tailored configurations that work within any organization's existing workflows. In a recent analysis of CHM member outcomes, HealthTap found that patients who spent 30 minutes in their initial PCP visit were significantly more likely to pursue preventive screenings. Compared to those with shorter visits, they were: 70% more likely to schedule colorectal cancer screenings; 43% more likely to schedule breast cancer screenings; 90% more likely to complete a diabetes screening; and 75% more likely to pursue hyperlipidemia screening 1. 'Primary care is the foundation of good health, but only if patients can actually access and sustain it,' said Sean Mehra, CEO and Co-founder of HealthTap. 'We've created a clinically rigorous, AI-enabled model that organizations can launch quickly out of the box, without heavy lift. At the same time, it's highly configurable and designed to integrate seamlessly into existing systems and workflows. Whether employers are looking for simplicity or scalability, we make it easy to deliver continuous, trusted care.' HealthTap's Direct Virtual Primary Care for Organizations is now available to any organization seeking to improve population health through stronger primary care access. About HealthTap HealthTap is a tech-enabled virtual physician practice available in all 50 states. We deliver high-quality, cost-effective primary care through our direct-to-consumer model and in partnership with health cost-sharing organizations, DMEs, pharmacies, payers, providers, and chronic condition management companies. With a mission to place a primary care doctor at every American's fingertips, HealthTap combines a proprietary digital platform with a medical group of experienced, compassionate, board-certified, U.S.-licensed physicians. Patients can build long-term relationships with one doctor, message between video visits, and access same-day/week appointments and 365-day on-demand urgent care—for everything from new symptoms and chronic conditions to preventive screenings, prescriptions, and PCP-led behavioral health. Our platform integrates seamlessly into partners' existing workflows, EMRs, and care channels—making it easy to expand access with either out-of-the-box or custom implementation. We are payer-agnostic and highly flexible—able to bill individuals, organizations, or insurance companies across both commercial and government plans.
